HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

Clinical progress in the field of HER2-positive breast cancer therapy has been dramatically improved by understanding of the immune regulatory mechanisms of tumor microenvironment. Passive immunotherapy utilizing recombinant monoclonal antibodies (mAbs), particularly trastuzumab and pertuzumab has p...

Descripción completa

Detalles Bibliográficos
Autores principales: Arab, Atefeh, Yazdian-Robati, Rezvan, Behravan, Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223380/
https://www.ncbi.nlm.nih.gov/pubmed/31915932
http://dx.doi.org/10.1007/s00005-019-00566-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223380/
https://www.ncbi.nlm.nih.gov/pubmed/31915932
http://dx.doi.org/10.1007/s00005-019-00566-1

Ejemplares similares